Clinical trials: Malignant Melanoma
Melanoma
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
To Determine the feasibility, compliance and adherence to PreFED intervention in resectable melanoma patients initiating neoadjuvant Ipi/Nivo.
- Trial name
- NCT06548789
- Testing
- Prebiotic Xnack Packouts
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- M.D. Anderson Cancer Center
Vitiligo, Skin Melanoma
Defining the Role of the Skin Microbiome in Immune-related Adverse Events
The skin microbiome has been implicated in several cutaneous autoimmune pathologies such as psoriasis and atopic dermatitis. However, its role in vitiligo and vitiligo lesions occuring in patients receiving anti-PD-1 for…
- Trial name
- SKINBIOTA (NCT04734704)
- Testing
- skin swabs at lesional and non-lesional sites, skin swabs on skin
- Where
- France
- Volunteers
- 57 people
- Sponsor
- University Hospital, Bordeaux
Breast Cancer, Kidney Cancer
Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma
RATIONALE: Interferon alfa may interfere with the growth of cancer cells and slow the growth of cancer. PURPOSE: This phase I trial is studying the side effects and best dose of interferon alfa in treating patients with stage IV…
- Conditions
- Breast Cancer, Kidney Cancer, Lymphoma, Melanoma
- Trial name
- IFNa (NCT00276536)
- Testing
- recombinant interferon alpha-1b, IFN
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- The Cleveland Clinic
Breast Cancer, Prostate Cancer
Behavioral Weight Loss Program for Cancer Survivors in Maryland
Behavioral Weight Loss for Overweight and Obese Cancer Survivors in Maryland: A Demonstration Project
- Conditions
- Breast Cancer, Prostate Cancer, Melanoma (Skin), Endometrial Cancer
- Trial name
- ASPIRE (NCT04534309)
- Testing
- Written Weight Loss Material, Weight Loss App, Behavioral Lifestyle Weight Loss Intervention (Coaching)
- Where
- United States
- Volunteers
- 340 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin
Skin Cancer Among Outdoor Workers
This observational study examines skin cancer among workers who may have prolonged occupational exposure to sunlight. Long-term exposure to ultraviolet radiation from the sun is an important risk factor for several types of skin…
- Conditions
- Melanoma (Skin Cancer), Basal Cell Carcinoma of Skin, Squamous Cell Cancer of Head and Neck (SCCHN), Work Injury
- Trial name
- Skin Cancer Am (NCT07831083)
- Where
- Israel
- Volunteers
- 10,000 people
- Sponsor
- Assuta Medical Center
Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine
SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine
This phase I pilot trial studies the side effects of stereotactic radiosurgery and nivolumab in treating patients with newly diagnosed melanoma that has spread to the brain or spine.
- Conditions
- Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm in the Spine, Stage IV Skin Melanoma
- Trial name
- NCT02716948
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Stereotactic Radiosurgery
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Malignant Melanoma Stage III
Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma
DONIMI is a phase 1b trial testing the combination of domatinostat + nivolumab or nivolumab monotherapy in IFN-gamma signature high patients and of domatinostat + nivolumab or domatinostat + nivolumab + ipilimumab in IFN-gamma…
- Trial name
- DONIMI (NCT04133948)
- Testing
- Domatinostat, Nivolumab, Ipilimumab
- Where
- 2 sites in Australia, Netherlands
- Volunteers
- 44 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Melanoma
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
The primary objective of this trial is to compare the survival of patients with metastatic malignant melanoma treated with Taxoprexin Injection to those treated with Dacarbazine.
- Trial name
- NCT00087776
- Testing
- Taxoprexin, Dacarbazine
- Where
- United States
- Volunteers
- 393 people
- Sponsor
- American Regent, Inc.
Atopic Dermatitis, Contact Dermatitis
Exploratory Study of Natural Killer Cells in Human Skin
Natural Killer (NK) cells play a unique role during innate immune responses as they are able to recognize and eliminate, without specific sensitization, tumors, microbe-infected cells as well as allogeneic cells.In a first time…
- Conditions
- Atopic Dermatitis, Contact Dermatitis, Psoriasis, Lichen Planus
- Trial name
- NCT00824889
- Testing
- Biopsy and sample of blood
- Where
- France
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Melanoma
Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma
This open label, single country trial will test if local injection of low-dose ipilimumab and nivolumab, is safe and reduces the sentinel node positivity in high-risk stage II melanoma patients.
- Trial name
- MARIANE (NCT06240143)
- Testing
- Ipilimumab, Nivolumab
- Where
- 6 sites in Netherlands
- Volunteers
- 96 people
- Sponsor
- The Netherlands Cancer Institute
Unresectable or Metastatic Melanoma
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
This was a Phase 1, open-label, non-randomized study of the combination of NY-ESO-1 plus ipilimumab in patients with unresectable or metastatic melanoma for whom treatment with ipilimumab was indicated.
- Trial name
- NCT01810016
- Testing
- Ipilimumab, NY-ESO-1 Protein Vaccine, NY-ESO-1 OLP4 Vaccine with Poly-ICLC and Montanide
- Where
- 5 sites in United States, Australia
- Volunteers
- 8 people
- Sponsor
- Ludwig Institute for Cancer Research
Melanoma
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma
This is a multicenter, two-arm, open-label, randomized controlled phase III clinical trial to evaluate the efficacy and safety of tunlametinib capsule in comparison with the combination chemotherapy of investigator's choice in…
- Trial name
- NCT06008106
- Testing
- tunlametinib, paclitaxel +carboplatin, or temozolomide +cisplatin, or dacarbazine +cisplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Shanghai Kechow Pharma, Inc.
Melanoma
Continuous vs Intermittent Dabrafenib Plus Trametinib in BRAFV600 Mutant Stage 3 Unresectable or Metastatic Melanoma
This feasibility study aims to determine if intermittent dosing is deliverable, based on patient and professional willingness to take part in a randomised trial evaluating less rather than the standard durations of treatment.
- Trial name
- INTERIM (NCT03352947)
- Testing
- Dabrafenib, Trametinib
- Where
- United Kingdom
- Volunteers
- 79 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Uveal Melanoma
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with confirmed metastatic uveal melanoma.
- Trial name
- NCT01801358
- Testing
- AEB071, MEK162
- Where
- 7 sites in United States, France and 4 more
- Volunteers
- 38 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Naevi, Malignant Melanoma
Immunohistochemical Expression Patterns of microRNA Processing Enzyme Dicer in Cutaneous Malignant Melanoma, Benign and Dysplastic Melanocytic Naevi
MicroRNAs (miRNAs) are very small endogenous RNA molecules about 22-25 nucleotides in length, capable of post-transcriptional gene regulation.
- Trial name
- NCT00862914
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Ruhr University of Bochum
Uveal Melanoma
Adjuvant Tebentafusp in High Risk Ocular Melanoma
At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting.
- Trial name
- ATOM (NCT06246149)
- Testing
- Tebentafusp
- Where
- 15 sites in United States, Belgium and 7 more
- Volunteers
- 290 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node
Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement
This phase II trial studies how well encorafenib and binimetinib work before surgery in treating patients with BRAF V600-mutated stage IIIB-D melanoma that has spread to the lymph nodes.
- Conditions
- Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in Lymph Node, Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8
- Trial name
- NCT04221438
- Testing
- Binimetinib, Conventional Surgery, Encorafenib
- Where
- 10 sites in United States
- Volunteers
- 3 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Melanoma (Skin), Telemedicine
Safety and Avoidance of Futile Excisions Through Skin Tele-triage
The goal of this study is to estimate the triage values, efficiency and safety of tele-dermoscopic triage of skin lesions suspected of melanoma.
- Trial name
- SAFEST (NCT05982600)
- Testing
- Single Assessor Teledermatological triage (TDT), 2 people Teledermatological triage (TDT), 3 people Teledermatological triage (TDT)
- Where
- Denmark
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Herlev Hospital
Melanoma and Other Malignant Neoplasms of Skin, Metastatic Melanoma
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
You are being asked to take part in this study because you have advanced melanoma. The goal of this clinical research study is to learn if oral azacitidine (CC-486) and pembrolizumab (MK-3475) can help to control melanoma.
- Trial name
- NCT02816021
- Testing
- Azacitidine, Pembrolizumab
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Melanoma, Advanced Urothelial Carcinoma
Safety, Tolerability and Pharmacokinetics of TWP-101 in Patients With Advanced Melanoma and Urothelial Carcinoma
This study is a multi-center, phase Ia/Ib, open clinical study to evaluate the safety, tolerability and pharmacokinetics of TWP-101 in patients with advanced melanoma and urothelial carcinoma.
- Trial name
- NCT04871334
- Testing
- TWP-101
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Shandong TheraWisdom Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.